Mind Medicine (MindMed) Inc.
MNMD
$-0.13
Change (1 day)
$12.22
Year High
$2.41
Year Low
Categories
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
Mind Medicine (MindMed) Inc. (MNMD) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -85,575,000 | 46.41 M | 124.54 M | 103.87 M | |
| 2022 | -142,070,000 | 19.08 M | 169.99 M | 146.06 M | |
| 2021 | -133,539,000 | 12.34 M | 164 M | 137.22 M | |
| 2020 | -80,094,000 | 5.65 M | 81.52 M | 81.52 M | |
| 2019 | 5.08 K | -17,931 | 198.96 K | 2.94 M | 2.94 M |